Results 251 to 260 of about 10,864 (278)

Brimonidine for erythema caused by rosacea

Drug and Therapeutics Bulletin, 2014
Brimonidine gel (Mirvaso—Galderma) became available in February of this year for the symptomatic treatment of facial erythema associated with rosacea in adults.1 Here, we review the evidence on brimonidine gel and consider its place in the management of erythema associated with rosacea.
openaire   +2 more sources

Safety and efficacy of brimonidine in children with glaucoma

Journal of American Association for Pediatric Ophthalmology and Strabismus, 2001
Brimonidine is a relatively selective alpha-agonist, which reduces intraocular pressure (IOP) by decreasing aqueous production and increasing uveoscleral outflow. Brimonidine passes through the blood-brain barrier, potentially causing central nervous system (CNS) toxicity. There have been reports of bradycardia, hypotension, hypothermia, hypotonia, and
Laura B. Enyedi, Sharon F. Freedman
openaire   +3 more sources

Charles Bonnet syndrome precipitated by brimonidine

Archivos de la Sociedad Española de Oftalmología (English Edition), 2013
An 81-year-old woman with age-related macular degeneration and pseudoexfoliative glaucoma developed visual hallucinations (faces, flowers and frames) shortly after beginning brimonidine drops. Neurologic and psychiatric examination was normal. Visual hallucinations disappeared within 10 days after discontinuing the drug.The Charles Bonnet syndrome (CBS)
José Benítez-del-Castillo, J. Gil-de-Bernabé, Pedro Arriola-Villalobos, Julian Garcia-Sanchez, Enrique Santos-Bueso, M.R. García-Catalán, David Díaz-Valle   +6 more
openaire   +3 more sources

Uvéite antérieure et brimonidine

Journal Français d'Ophtalmologie, 2004
Nous rapportons le cas d’un patient de 66 ans traite depuis 13 mois par brimonidine et presentant de facon bilaterale une uveite anterieure granulomateuse hypertensive associee a une allergie oculopalpebrale intense. Le bilan n’a retrouve aucune etiologie et l’evolution a ete rapidement favorable a l’arret de la brimonidine. Cette description montre qu’
L. Velasque, R. Vignal, F. Ducousso, V. Deral, L. Pernod   +4 more
openaire   +2 more sources

Effects of 0.2% Brimonidine on Ocular Anterior Structures

Journal of Ocular Pharmacology and Therapeutics, 1999
The aim of the study was to evaluate the effect of an alpha2-adrenergic agonist, 0.2% brimonidine, on a number of echobiometry and ultrasound biomicroscopy ocular parameters. Ten healthy subjects ranging in age from 20 to 40 years (mean age 29+/-3.39) were recruited into this prospective open-label trial.
Marchini G., Babighian S., Tosi R., Bonomi L.   +3 more
openaire   +2 more sources

Brimonidine (Alphagan) associated anterior uveitis: Table 1

British Journal of Ophthalmology, 2012
Brimonidine is a well-recognised cause of ocular surface disease but is less widely known to cause uveitis. We present important clinical lessons from five new cases of brimonidine-associated anterior uveitis. 1. A 64-year-old man with primary open-angle glaucoma presented with red eyes and visual halos.
Charlotte M McKnight, William H. Morgan, Dru Daniels, Josephine C Richards   +3 more
openaire   +3 more sources

Vitreous and Aqueous Concentrations of Brimonidine Following Topical Application of Brimonidine Tartrate 0.1% Ophthalmic Solution in Humans

Journal of Ocular Pharmacology and Therapeutics, 2015
To determine the vitreous and aqueous concentrations of brimonidine after topical application of the ophthalmic solution 0.1%.The prospective observational case series included patients with an idiopathic epiretinal membrane or macular hole who were scheduled for a pars plana vitrectomy.
Seiko Kozai, Masaru Inatani, Shogo Arimura, Yoshihiro Takamura, Yuji Takihara, Takehiro Matsumura, Satoshi Yokota, Satoshi Yokota, Takeshi Tomomatsu   +8 more
openaire   +2 more sources

Development of brimonidine niosomes laden contact lenses for extended release and promising delivery system in glaucoma treatment.

DARU, 2023
Shresthi Tripathi, K. Yadav
semanticscholar   +1 more source

Twelve-Month Evaluation of Brimonidine-Purite Versus Brimonidine in Patients With Glaucoma or Ocular Hypertension

Journal of Glaucoma, 2002
To compare the efficacy and safety of brimonidine-Purite (Alphagan; Allergan, Irvine, CA) 0.15% and 0.2% three times daily with brimonidine (Alphagan) 0.2% three times daily in patients with glaucoma or ocular hypertension.In this 12-month, randomized, multicenter, double-masked, parallel-group study, patients were randomly assigned to receive ...
openaire   +3 more sources

Brimonidine Allergy Presenting as Vernal-like Keratoconjunctivitis

Journal of Glaucoma, 2015
To report a brimonidone-induced allergic reaction that mimicked a limbal form of vernal keratoconjunctivitis in the setting of background ocular surface toxicity.A 78-year-old male with a history of primary open angle glaucoma presented with symptoms of unilateral blurry vision, irritation, and redness shortly after starting brimonidine exclusively in ...
Yasha S. Modi, Aparna A. Shah, Sarah R. Wellik, Anat Galor, Benjamin J. Thomas   +4 more
openaire   +2 more sources